An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
Kyowa Kirin, Inc.
Emma Guttman-Yassky; Eric L Simpson; Kristian Reich; Kenji Kabashima; Ken Igawa; Tetsuya Suzuki; Hirotaka Mano; Takeshi Matsui; Ehsanollah Esfandiari; Masutaka Furue